Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Behavioral Comorbidities and Drug Treatments in a Zebrafish scn1lab Model of Dravet Syndrome.

eNeuro - 1 Jan 2000

Grone Brian P, Qu Tiange, Baraban Scott C

Abstract excerpt

Loss-of-function mutations in SCN1A cause Dravet syndrome (DS), a catastrophic childhood epilepsy in which patients experience comorbid behavioral conditions, including movement disorders, sleep abnormalities, anxiety, and intellectual disability. To study the functional consequences of voltage-gated sodium channel mutations, we use zebrafish with a loss-of-function mutation in scn1lab, a zebrafish homolog of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants
Share to Cognitive Behavioral Therapy
Share to Epilepsies, Myoclonic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exploratory Behavior

Share to Interneurons

Share to Locomotion

Share to NAV1.1 Voltage-Gated Sodium Channel

Share to Sleep Wake Disorders

Source

Open in PubMed Open full text

Identifiers

PMID: 28812061
DOI: 10.1523/ENEURO.0066-17.2017
PMCID: PMC5555352

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Behavioral Comorbidities and Drug Treatments in a Zebrafish scn1lab Model of Dravet Syndrome.PMID 28812061Read ↗

Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment.Semantic proximity Read ↗

Testing of putative antiseizure drugs in a preclinical Dravet syndrome zebrafish modelSemantic proximity Read ↗

Testing of putative antiseizure medications in a preclinical Dravet syndrome zebrafish modelSemantic proximity Read ↗

Pharmacological Characterization of an Antisense Knockdown Zebrafish Model of Dravet Syndrome: Inhibition of Epileptic Seizures by the Serotonin Agonist FenfluramineSemantic proximity Read ↗

NaV1.1 and NaV1.6 selective compounds reduce the behavior phenotype and epileptiform activity in a novel zebrafish model for Dravet Syndrome.Semantic proximity Read ↗

NaV1.1 and NaV1.6 selective compounds reduce the behavior phenotype in a novel zebrafish model for Dravet SyndromeSemantic proximity Read ↗

New insights into the early mechanisms of epileptogenesis in a zebrafish model of Dravet syndromeSemantic proximity Read ↗

Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndromeSemantic proximity Read ↗

Pharmaco-behavioral profiling identifies suppressors of autism gene-associated phenotypes in zebrafish.Semantic proximity Read ↗

Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet SyndromeSemantic proximity Read ↗

Serotonergic Modulation as Effective Treatment for Dravet Syndrome in a Zebrafish Mutant Model.Semantic proximity Read ↗

Zebrafish Larvae Carrying a Splice Variant Mutation in cacna1d: A New Model for Schizophrenia-Like Behaviours?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.